Vivus sues Actavis

|By:, SA News Editor

Vivus (VVUS +0.6%) files a lawsuit in the U.S. District Court for the District of New Jersey against Actavis' (ACT -1.1%) ANDA to market and sell a generic version of Qsymia.

Since Vivus filed its suit within 45 days of the certification notice, the court will automatically issue a 30-month stay of the FDA's approval decision (the stay could be shorter if the court finds that the Qsymia patents are invalid, unenforceable or not infringed).